The estimated Net Worth of David Mc Clung is at least $451 Thousand dollars as of 5 November 2018. Mr. Clung owns over 1,600 units of BioCardia stock worth over $16,864 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $434,495 as Chief Financial Officer at BioCardia.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. McClung BCDA stock SEC Form 4 insiders trading
David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.
The largest trade he's ever made was buying 2,850 units of BioCardia stock on 25 September 2018 worth over $6,983. On average, David trades about 886 units every 33 days since 2018. As of 5 November 2018 he still owns at least 6,200 units of BioCardia stock.
You can see the complete history of Mr. Clung stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David McClung biography
David McClung CPA serves as Chief Financial Officer of the Company. He has served as our Chief Financial Officer since September 2017 and has been with the Company since September 2013, also serving as Vice President of Finance from March 2016 to August 2017 and as Senior Director of Finance & Controller from September 2013 to February 2016. Mr. McClung has more than 20 years of finance and accounting experience in publicly and privately financed organizations, including startup enterprises, large public companies and middle-market businesses. Before joining our company, Mr. McClung served as Director of Finance and Controller at Sonitus Medical, Inc., a privately-held manufacturer of an FDA cleared prosthetic hearing device for the treatment of single-sided deafness and conductive hearing loss, from June 2011 to August 2013. Prior to that, Mr. McClung served as Controller at NextWave Pharmaceuticals, Inc. a specialty pharmaceutical company acquired by Pfizer, Inc., from April 2010 to June 2011. Mr. McClung spent his early career in public accounting and finance functions at other companies, including Matson Navigation, Inc., The Clorox Company and KPMG LLP. Mr. McClung earned a Bachelor of Arts degree in Accounting from Georgia State University, graduating with honors. He is an actively licensed CPA and member of the AICPA and the California Society of CPAs.
What is the salary of David McClung?
As the Chief Financial Officer of BioCardia, the total compensation of David McClung at BioCardia is $434,495. There are 2 executives at BioCardia getting paid more, with Peter Altman having the highest compensation of $677,501.
How old is David McClung?
David McClung is 56, he's been the Chief Financial Officer of BioCardia since 2020. There are 10 older and 4 younger executives at BioCardia. The oldest executive at BioCardia Inc. is Simon Stertzer, 83, who is the Independent Chairman of the Board.
What's David McClung's mailing address?
David's mailing address filed with the SEC is C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE, CA, 94085.
Insiders trading at BioCardia
Over the last 8 years, insiders at BioCardia have traded over $2,555,815 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer, and Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of $1,321,186. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth $55,815.
What does BioCardia do?
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
What does BioCardia's logo look like?
Complete history of Mr. Clung stock trades at BioCardia
BioCardia executives and stock owners
BioCardia executives and other stock owners filed with the SEC include:
-
Peter Altman,
President, Chief Executive Officer, Director -
Henricus Duckers,
Chief Medical Officer -
David McClung,
Chief Financial Officer -
Dr. Peter A. Altman,
CEO, Pres & Director -
David McClung,
Chief Financial Officer -
Phil Pesta,
Vice President - Operations -
Richard Krasno,
Independent Director -
Simon Stertzer,
Independent Chairman of the Board -
Richard Pfenniger,
Independent Director -
Jay Moyes,
Independent Director -
Fernando Fernandez,
Independent Director -
Andrew Blank,
Independent Director -
Jim Allen,
Independent Director -
Dr. Sujith Shetty,
Chief Medical Officer and VP of Clinical & Regulatory -
Edward M. Gillis,
Sr. VP of Devices -
Dr. Ian McNiece Ph.D.,
Chief Scientific Officer -
Allan R Tessler,
Director -
Richard T Allen,
Vice President of Quality -
Thomas Quertermous,
Director -
Eric Duckers,
Chief Medical Officer -
Phillip Md Et Al Frost Gamm...,